课题基金 / 基金详情

The Atp7b-/- mouse model of neurological copper toxicity and Wilson Disease

The Atp7b-/- mouse model of neurological copper toxicity and Wilson Disease
Atp7b-/- 神经铜毒性和威尔逊病小鼠模型
批准号:
10574028
负责人:
JASON L BURKHEAD
金额:
$41.48万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-09-20 至 2024-08-31

项目摘要

项目成果

JASON L BURKHEAD的其他基金

相似基金

相关文献

中文摘要
翻译
肝豆状核变性(WD)是由ATP7B基因突变引起的遗传性铜代谢紊乱 这会导致致病性铜在大脑和肝脏中堆积。WD的神经系统症状可能很严重或 致命的,包括肌张力障碍、共济失调和帕金森样震颤。患者通常表现出多种特征的组合。 WD患者也可能出现精神症状(通常在WD诊断之前),包括行为 变化、个性变化、焦虑和抑郁。WD治疗的一个主要挑战是神经学 当使用D-青霉胺等降铜药物时,症状往往会恶化。锌盐是 这是一种治疗WD的替代疗法,与神经退化关系较小。然而,治疗 锌对肝病的疗效似乎是有限的,神经症状的改善是 相对较慢。神经系统WD治疗研究的一个重大障碍是有限的发展 用于研究疾病机制和治疗的临床前动物模型。WD的啮齿动物模型已经被 确定铜中毒的肝脏机制是非常有价值的,而在神经学WD中的实用性不是很好 探索过了。ATP7B-/-小鼠是WD肝脏病理的高度特征化的啮齿动物模型,揭示了 与人类相比,脂肪代谢、肝脏损伤和相对发病年龄。我们最近使用了这个模型来 确定锌代谢改变是WD铜中毒的机制。ATP7B-/-小鼠脑内铜含量 在一生中增加,这与WD患者脑内铜的积累相平行。这项工作将决定 ATP7B-/-小鼠在神经性WD临床前研究中的应用。拟议的实验将定义 脑铜水平改变的行为和分子反应以及WD治疗对脑内铜含量的影响 这些表型。一种综合的方法将检验ATP7B-/-小鼠建立神经学模型的假设 WD用于机械性疾病和治疗研究。这个假设将通过执行 以下三个具体目标:目标1:确定ATP7B-/-、ATP7B+/-小鼠表现出运动的程度 和行为障碍。将确定雄性和雌性动物的行为表型 三种处理条件下的野生型/杂合型(ATP7B+/+/ATP7B+/-)和基因敲除型(ATP7B-/-) (未处理的,D-青霉胺,或锌);目标2:确定锌或D-青霉胺治疗对 ATP7B-/-、ATP7B+/-和野生型脑组织中痕量金属和氧化应激标志物的浓度 小鼠;目的3:测定动物脑内靶区域铜和锌处理蛋白水平的变化 接受对照、锌或螯合剂处理。这项研究的完成将为 在ATP7B-/-小鼠和WD患者中进行以治疗为重点的实验,以改善患者的预后。 确定铜中毒对大脑的影响也将建立对其他神经疾病的洞察 铜的蓄积包括帕金森氏症和阿尔茨海默氏症。
英文摘要
Wilson Disease (WD) is an inherited disorder of copper metabolism caused by mutation in the ATP7B gene that causes pathogenic copper accumulation in the brain and liver. WD neurologic symptoms can be severe or fatal and include dystonia, ataxia and Parkinson-like tremor. Patients often present a combination of features. WD patients may also present with psychiatric symptoms (often prior to WD diagnosis) including behavioral changes, personality changes, anxiety and depression. A major challenge in WD treatment is that neurological symptoms often worsen when copper-lowering drugs such as D-penicillamine are administered. Zinc salts are an alternative treatment for WD and less associated with neurological degradation. However, treatment efficacy of zinc for liver disease appears to be limited, and improvement in neurologic symptoms is comparatively slow. A significant obstacle in research on neurologic WD treatment is the limited development of pre-clinical animal models to study disease mechanisms and treatments. Rodent models of WD have been invaluable to define hepatic mechanisms of copper toxicosis, while utility in neurologic WD is not well explored. The Atp7b-/- mouse is a highly characterized rodent model of WD liver pathology, revealing defects in lipid metabolism, liver damage and relative age-of-onset compared to humans. We recently used this model to identify altered zinc metabolism as mechanism of copper toxicity in WD. Brain copper in the Atp7b-/- mouse increases throughout life, which parallels brain copper accumulation in WD patients. This work will determine the utility of the Atp7b-/- mouse for pre-clinical studies of neurologic WD. Proposed experiments will define behavioral and molecular responses of altered brain copper levels as well as the impacts of WD treatments on these phenotypes. An integrative approach will test the hypothesis that the Atp7b-/- mouse models neurologic WD for mechanistic disease and treatment studies. This hypothesis will be tested through execution of the following three Specific Aims: Aim 1: Determine the extent to which Atp7b-/-, Atp7b+/- mice exhibit motor and behavioral impairments. Behavioral phenotypes will be determined for male and female animals of both wildtype/heterozygous (Atp7b+/+/Atp7b+/-) and knockout (Atp7b-/-) genotypes for three treatment conditions (untreated, D-penicillamine, or zinc); Aim 2: Determine the effects of Zn or D-penicillamine treatment on the concentration of trace metals and markers of oxidative stress in the brain for Atp7b-/-, Atp7b+/- and wild type mice; Aim 3: Determine the changes in Cu and Zn handling protein levels in target brain regions of animals subjected to control, Zn or chelator treatments. Completion of this study will provide a foundation for treatment-focused experiments in the Atp7b-/- mouse and WD patients to improve patient outcomes. Identifying effects of copper toxicity in the brain will also build insight into other neurological disorders with copper accumulation including Parkinson’s and Alzheimer’s diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Rethinking the zinc-copper relationship in Wilson Disease
  • 批准号:
    10515079
  • 项目类别:
  • 资助金额:
    $43.97万
  • 财政年份:
    2017
  • 负责人:
    JASON L BURKHEAD
  • 依托单位:
INBRE-2 MAMMALIAN COPPER METABOLISM
  • 批准号:
    8359583
  • 项目类别:
  • 资助金额:
    $13.06万
  • 财政年份:
    2011
  • 负责人:
    JASON L BURKHEAD
  • 依托单位:
INBRE-2 MAMMALIAN COPPER METABOLISM
  • 批准号:
    8167410
  • 项目类别:
  • 资助金额:
    $17.74万
  • 财政年份:
    2010
  • 负责人:
    JASON L BURKHEAD
  • 依托单位:
Bioinformatics Core
  • 批准号:
    9981784
  • 项目类别:
  • 资助金额:
    $31.31万
  • 财政年份:
    2001
  • 负责人:
    JASON L BURKHEAD
  • 依托单位:
海外基金